Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Encorafenib (colorectal cancer, first line) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A26-88
Last updated

Report documents

  1. Extract of dossier assessment

    Encorafenib (colorectal cancer, first line) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 275 kB, DE, not accessible
    Download file : Extract of dossier assessment (PDF document, 275 kB, DE, not accessible)

  2. Dossier assessment

    Encorafenib (colorectal cancer, first line) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 2 MB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A26-88
    Download file : Dossier assessment (PDF document, 2 MB, DE, not accessible)

Dossier assessment

Indication:

Adult patients with metastatic colorectal cancer (MCRC) with a BRAF V600E mutation in first-line treatment

Result of dossier assessment:

Indication of a considerable added benefit

Press releases

Encorafenib for colorectal cancer: multi-comparator study yields indication of considerable added benefit

If the standard of care in the comparator arm is not the same for all patients, studies often fail to reflect this. The example of encorafenib in metastatic colorectal cancer demonstrates that such studies are feasible.
Press release

Project details

Project no.
A26-88
Commission
Commission awarded on 15.07.2026 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A26-88

Connected Projects

  1. Dossier assessment

    Encorafenib (melanoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A18-61
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Encorafenib (colorectal cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-56
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Binimetinib and encorafenib (NSCLC) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-100
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Binimetinib and encorafenib (NSCLC) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-101
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page